What were Jubilant Pharmova Ltd's latest quarterly results?
Jubilant Pharmova Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: -44.6% (inflecting downward)
- Revenue Growth YoY: +16.5%
- Operating Margin: 14.0% (stable)
Jubilant Pharmova Ltd: Why Is It Outperforming Nifty 500?
ActiveWeakNew This Week
In , Jubilant Pharmova Ltd (Pharma - API & CRAMS) is outperforming Nifty 500 with +8.9% relative strength. Fundamentals: Weak.
Jubilant Pharmova Ltd Key Facts
- PE Ratio
- 34.8x
- Market Cap
- ₹16,061 Cr
- PAT Growth YoY
- -45%
- Revenue Growth YoY
- +17%
- OPM
- 14.0%
- RS vs Nifty 500
- +8.9%
PE: Mid ContractionFalling Knife
What's Happening
🔻Earnings declining and PE falling — fundamentals deteriorating
👔Promoter stake down 3.0% this quarter
🌐FII stake decreased 1.4% this quarter
🏛️DII accumulation — stake up 4.9%
Key Numbers
PAT Growth YoY
-45%
Inflection Down
Revenue YoY
+17%
Accelerating
Operating Margin
14.0%
-200 bps YoY
PE Ratio
34.8
Current Price
₹1,008
Dividend Yield
0.50%
Fundamental Score
32/100
Weak
3Y PAT CAGR
+27%
Market Cap
16.1K Cr
Valuation
N/A12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
How Fast Is Jubilant Pharmova Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +17% | +6% | Accelerating |
| PAT (Net Profit) | -45% | +27% | Inflection Down |
| OPM | 14.0% | -200 bps | Stable |
Other Top Pharma - API & CRAMS Stocks Beating Nifty 500
Frequently Asked Questions: Jubilant Pharmova Ltd
Based on publicly available financial data. This is educational research, not investment advice.
Is Jubilant Pharmova Ltd's profit growing or declining?
Jubilant Pharmova Ltd's profit is declining with an inflecting downward trend.
- PAT Growth YoY: -44.6% (latest quarter)
- PAT Growth QoQ: -53.3% (sequential)
- 3-Year PAT CAGR: +26.5%
- Trend: Inflecting downward — consistent growth pattern
What is Jubilant Pharmova Ltd's revenue growth trend?
Jubilant Pharmova Ltd's revenue growth trend is accelerating.
- Revenue Growth YoY: +16.5%
- Revenue Growth QoQ: +7.9% (sequential)
- 3-Year Revenue CAGR: +5.7%
How is Jubilant Pharmova Ltd's operating margin trending?
Jubilant Pharmova Ltd's operating margin is stable.
- Current OPM: 14.0%
- OPM Change YoY: -2.0% basis points
- OPM Change QoQ: -3.0% basis points
What is Jubilant Pharmova Ltd's 3-year profit and revenue CAGR?
Jubilant Pharmova Ltd's long-term compounding rates
- 3-Year Profit CAGR: +26.5%
- 3-Year Revenue CAGR: +5.7%
Is Jubilant Pharmova Ltd's growth accelerating or decelerating?
Jubilant Pharmova Ltd's earnings growth is inflecting downward with mixed signals on a sequential basis.
- YoY Acceleration: -62.2% bps
- Sequential Acceleration: -67.6% bps
What is Jubilant Pharmova Ltd's trailing twelve month (TTM) performance?
Jubilant Pharmova Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹429 Cr
- TTM PAT Growth: -31.1% YoY
- TTM Revenue: ₹8,000 Cr
- TTM Revenue Growth: +12.1% YoY
- TTM Operating Margin: 16.0%
What is Jubilant Pharmova Ltd's current PE ratio?
Jubilant Pharmova Ltd's current PE ratio is 34.8x.
- Current PE: 34.8x
- Market Cap: 16.1K Cr
- Dividend Yield: 0.50%
What is Jubilant Pharmova Ltd's price-to-book ratio?
Jubilant Pharmova Ltd's price-to-book ratio is 2.4x.
- Price-to-Book (P/B): 2.4x
- Book Value per Share: ₹414
- Current Price: ₹1008
Is Jubilant Pharmova Ltd a fundamentally strong company?
Jubilant Pharmova Ltd is rated Weak with a fundamental score of 32.03/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +16.5% (10% weight)
- PAT Growth YoY: -44.6% (10% weight)
- PAT Growth QoQ: -53.3% (10% weight)
- Margins stable (10% weight)
Is Jubilant Pharmova Ltd debt free?
Jubilant Pharmova Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹3,000 Cr
What is Jubilant Pharmova Ltd's return on equity (ROE) and ROCE?
Jubilant Pharmova Ltd's return ratios over recent years
- FY2023: ROCE 3.0%
- FY2024: ROCE 7.0%
- FY2025: ROCE 10.0%
Is Jubilant Pharmova Ltd's cash flow positive?
Jubilant Pharmova Ltd's operating cash flow is positive (FY2025).
- Cash from Operations (CFO): ₹1,000 Cr
- Free Cash Flow (FCF): ₹2,000 Cr
- CFO/PAT Ratio: 128% (strong cash conversion)
What is Jubilant Pharmova Ltd's dividend yield?
Jubilant Pharmova Ltd's current dividend yield is 0.50%.
- Dividend Yield: 0.50%
- Current Price: ₹1008
Who holds Jubilant Pharmova Ltd shares — promoters, FII, DII?
Jubilant Pharmova Ltd's shareholding pattern (Mar 2026)
- Promoters: 47.7%
- FII (Foreign): 15.9%
- DII (Domestic): 11.6%
- Public: 24.3%
Is promoter holding increasing or decreasing in Jubilant Pharmova Ltd?
Jubilant Pharmova Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 47.7% (Mar 2026)
- Previous Quarter: 47.7% (Dec 2025)
- Change: 0.00% (stable)
How long has Jubilant Pharmova Ltd been outperforming Nifty 500?
Jubilant Pharmova Ltd has been outperforming Nifty 500 for 1 consecutive week, indicating early-stage outperformance.
Is Jubilant Pharmova Ltd a new momentum entry or an established outperformer?
Jubilant Pharmova Ltd is a new entry this week — it just started outperforming Nifty 500. New entries are worth monitoring for follow-through.
Is Jubilant Pharmova Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Jubilant Pharmova Ltd may be worth studying
- Revenue growth is accelerating — +16.5% YoY
- Cash flow is positive — CFO ₹1,000 Cr
What is the investment thesis for Jubilant Pharmova Ltd?
Jubilant Pharmova Ltd investment thesis summary:
Research Signals (Bull Case)
- Revenue growing at +16.5% YoY
What is the future outlook for Jubilant Pharmova Ltd?
Jubilant Pharmova Ltd's forward outlook based on current data signals
- Earnings Trend: inflecting downward
- Revenue Trend: accelerating
- Margin Trend: stable
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.